|
|
Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2002-01-0104.
Submitted January 14, 2002
Accepted July 22, 2002
Expression of MUM1/IRF4 Correlates with Clinical Outcome in Patients with B-cell Chronic Lymphocytic Leukemia
Chung-Che Chang*, Jennifer Lorek, Daniel E Sabath, Ying Li, Christopher R Chitambar, Brent Logan, Bal Kampalath, and Ronald P Cleveland
Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA
Department of Pathology, Case Western Reserve, Cleveland, OH, USA
* Corresponding author; email: jeffchang{at}pol.net.
In this study, we evaluated the prognostic significance of MUM1/IRF4 expression in B-CLL. Our results demonstrated that the absence of MUM1/IRF4 expression showed the highest relative risk among the factors analyzed in determining the probability of dying in B-CLL cases by univariate and multivariate Cox regression analysis. Patients without MUM1/IRF4 expression had a significantly worse overall survival than those with MUM1/IRF4 expression (52% cumulative survival: 63 months vs. not reached, Kaplan-Meier survival analysis, p < 0.03, Logrank test). Patients with MUM1/IRF4 expression were more likely to present with low Rai stage and interstitial/nodular marrow involvement. Furthermore, only one of 11 patients with MUM1/IRF4 expression and interstitial/nodular marrow involvement died with a follow up length up to 100 months. Our results suggest that B-CLL with expression of MUM1/IRF4, indicative of post germinal center origin, has a much more favorable clinical course and that MUM1/IRF4 is an important prognostic marker in B-CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. ter Brugge, V. B. T. Ta, M. J. W. de Bruijn, G. Keijzers, A. Maas, D. C. van Gent, and R. W. Hendriks
A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen
Blood,
July 2, 2009;
114(1):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ramos-Vara, M. A. Miller, and V. E. O. Valli
Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20
Vet. Pathol.,
November 1, 2007;
44(6):
875 - 884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Valsami, V. Pappa, D. Rontogianni, F. Kontsioti, E. Papageorgiou, J. Dervenoulas, T. Karmiris, S. Papageorgiou, N. Harhalakis, N. Xiros, et al.
A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4
Haematologica,
October 1, 2007;
92(10):
1343 - 1350.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Naresh
MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes
Haematologica,
February 1, 2007;
92(2):
267 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Hoefnagel, R. Dijkman, K. Basso, P. M. Jansen, C. Hallermann, R. Willemze, C. P. Tensen, and M. H. Vermeer
Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling
Blood,
May 1, 2005;
105(9):
3671 - 3678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S E Coupland, M Hellmich, C Auw-Haedrich, W R Lee, I Anagnostopoulos, and H Stein
Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases
Br J Ophthalmol,
March 1, 2005;
89(3):
352 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
